Published in J Am Coll Cardiol on August 01, 1997
Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ (2000) 2.47
Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation (2012) 2.17
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA (2016) 2.05
Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol (2010) 1.92
Insulin resistance in pulmonary arterial hypertension. Eur Respir J (2008) 1.80
Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev (2012) 1.61
Chronic heart failure reduces Akt phosphorylation in human skeletal muscle: relationship to muscle size and function. J Appl Physiol (1985) (2010) 1.59
Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res (2013) 1.56
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol (2007) 1.52
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail (2010) 1.49
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab (2014) 1.48
Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation. Clin Sci (Lond) (2010) 1.44
Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest (2010) 1.34
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol (2014) 1.27
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol (2010) 1.21
A common trafficking route for GLUT4 in cardiomyocytes in response to insulin, contraction and energy-status signalling. J Cell Sci (2009) 1.16
Caloric restriction and growth hormone receptor knockout: effects on expression of genes involved in insulin action in the heart. Exp Gerontol (2006) 1.13
Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol (2003) 1.12
Origin of symptoms in chronic heart failure. Heart (2005) 1.10
Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ Res (2012) 1.10
Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol (2007) 1.09
Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart (2005) 1.05
Hypothalamic mechanisms in cachexia. Physiol Behav (2010) 1.04
Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in the failing rat heart. Cardiovasc Res (2012) 0.97
Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol (2010) 0.94
The metabolic syndrome and the heart--a considered opinion. Clin Res Cardiol (2006) 0.92
Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health (2007) 0.90
Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Cardiovasc Diabetol (2011) 0.90
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol (2013) 0.89
The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. J Cardiovasc Pharmacol (2008) 0.89
Skeletal muscle mitochondrial density, gene expression, and enzyme activities in human heart failure: minimal effects of the disease and resistance training. J Appl Physiol (1985) (2012) 0.88
GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail (2014) 0.88
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. J Am Heart Assoc (2016) 0.87
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail (2016) 0.85
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz (2009) 0.85
Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series). Pulm Circ (2015) 0.85
Amino acids and derivatives, a new treatment of chronic heart failure? Heart Fail Rev (2015) 0.83
T(-786)→C polymorphism of the endothelial nitric oxide synthase gene is associated with insulin resistance in patients with ischemic or non ischemic cardiomyopathy. BMC Med Genet (2012) 0.83
Insulin signalling and resistance in patients with chronic heart failure. J Physiol (2003) 0.82
Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies. PLoS One (2013) 0.81
Animal models of insulin resistance and heart failure. Heart Fail Rev (2014) 0.78
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study. Cardiovasc Diabetol (2011) 0.78
Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging. Am J Nucl Med Mol Imaging (2012) 0.78
Association between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompensated acute heart failure. Heart Vessels (2016) 0.77
Insulin effects on cardiac Na+/Ca2+ exchanger activity: role of the cytoplasmic regulatory loop. J Biol Chem (2008) 0.77
Heart failure in acute ischemic stroke. Curr Cardiol Rev (2010) 0.77
Insulin resistance: marker or mediator? Am J Med (2009) 0.77
Is there an estrogenic component in the metabolic syndrome? Genes Nutr (2006) 0.77
β-Adrenergic Receptor and Insulin Resistance in the Heart. Biomol Ther (Seoul) (2017) 0.77
Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure. Sci Rep (2015) 0.76
Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Fail (2013) 0.76
Diminishing impairments in glucose uptake, mitochondrial content, and ADP-stimulated oxygen flux by mesenchymal stem cell therapy in the infarcted heart. Am J Physiol Cell Physiol (2013) 0.76
The effect of chronic heart failure and type 2 diabetes on insulin-stimulated endothelial function is similar and additive. Vasc Health Risk Manag (2011) 0.76
Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J Neurol (2017) 0.76
Malnutrition and Gut Flora Dysbiosis: Specific Therapies for Emerging Comorbidities in Heart Failure. Biomed Res Int (2015) 0.75
A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus. Vasc Health Risk Manag (2007) 0.75
Mandatory oral glucose tolerance tests identify more diabetics in stable patients with chronic heart failure: a prospective observational study. Diabetol Metab Syndr (2014) 0.75
Effects of Beta-Blocker Titration on Glucose Homeostasis in Heart Failure. J Pharm Technol (2009) 0.75
Sustained βAR Stimulation Mediates Cardiac Insulin Resistance in a PKA-Dependent Manner. Mol Endocrinol (2015) 0.75
Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Heart (1999) 0.75
Regulating PPARδ signaling as a potential therapeutic strategy for skeletal muscle disorders in heart failure. Am J Physiol Heart Circ Physiol (2015) 0.75
Obesity and Cardiac Function - The Role of Caloric Excess and its Reversal. Drug Discov Today Dis Mech (2013) 0.75
Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation. Circ Heart Fail (2016) 0.75
[Diabetes and heart failure]. Herz (2010) 0.75
Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol (1997) 16.86
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
Cardiologists rebuked. Lancet (1994) 3.85
Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J (2001) 3.49
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
Thiamine in our bread and wine? Med J Aust (1990) 3.09
The endotoxin-lipoprotein hypothesis. Lancet (2000) 3.03
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2000) 2.85
Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J (1998) 2.73
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 2.69
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet (2003) 2.64
Differences in proximal femur bone density over two centuries. Lancet (1993) 2.51
Practice nurses' workload and consultation patterns. Br J Gen Pract (1995) 2.50
Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax (2001) 2.50
Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ (2000) 2.47
Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart (2008) 2.45
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Bone-density measurement. Lancet (1992) 2.38
Screening for hypertrophic cardiomyopathy. BMJ (1993) 2.31
Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med (1995) 2.31
Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1997) 2.27
Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr (1992) 2.23
Survey of diabetic retinopathy screening services in England and Wales. Diabet Med (1998) 2.22
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol (1997) 2.08
Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther (1999) 2.06
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J (2000) 2.06
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1997) 2.05
Second trimester ambulatory blood pressure in nulliparous pregnancy: a useful screening test for pre-eclampsia? Br J Obstet Gynaecol (1993) 2.04
Evidence for a new sibling species of Anopheles minimus from the Ryukyu Archipelago, Japan. J Am Mosq Control Assoc (2001) 2.03
Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. BMJ (1995) 1.99
Insulin resistance and cigarette smoking. Lancet (1992) 1.98
Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J (1998) 1.97
Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation (1996) 1.88
The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J (1997) 1.80
Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. Am J Cardiol (2001) 1.79
Postmenopausal osteoporosis. Br Med J (Clin Res Ed) (1983) 1.77
Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol (1996) 1.76
Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation (2001) 1.75
Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation (2000) 1.72
Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol (2001) 1.71
Calcitonin for prevention of postmenopausal bone loss. Lancet (1988) 1.71
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol (1999) 1.71
Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Restrictive physiology predicts superior exercise performance. Circulation (1995) 1.70
Insulin resistance: syndrome or tendency? Lancet (1995) 1.69
Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. Eur Heart J (2000) 1.66
Bombesin: action on gut hormones and calcium in man. J Clin Endocrinol Metab (1982) 1.65
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol (1997) 1.63
Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs (1994) 1.61
Maintenance oral nifedipine for preterm labor: a randomized clinical trial. Am J Obstet Gynecol (1999) 1.60
Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis (1993) 1.57
Characteristics of phasic and tonic sympathetic ganglion cells of the guinea-pig. J Physiol (1986) 1.57
Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J (1997) 1.55
Retracted Altered calcitonin gene in a young patient with osteoporosis. BMJ (1989) 1.55
Modified method of spinal computed tomography for trabecular bone mineral measurements. J Comput Assist Tomogr (1986) 1.53
Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J (2001) 1.53
MR imaging and CT of orbital infections and complications in acute rhinosinusitis. Radiol Clin North Am (1998) 1.52
Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J (1995) 1.50
Heart Failure 99 -- the MOXCON story. Int J Cardiol (1999) 1.48
Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet (1981) 1.47
Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric (2011) 1.47
Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severely impaired left ventricular function. Eur Heart J (2001) 1.47
Adrenal mass with virilisation: importance of endocrine investigation. BMJ (1996) 1.46
A physiological role for calcitonin: protection of the maternal skeleton. Lancet (1979) 1.44
Hormone replacement therapy: where we stand in Europe. Eur Heart J (2001) 1.44
The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J (1999) 1.44